Skip to content

12 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

RSV Disease Burden in Adults in Emerging Market Countries, a Systematic Review and Modelling Analysis

The estimated incidence and proportion positive of RSV disease in EMC is substantially lower than HIC, and narrow case definitions requiring fever, less sensitive testing such as direct fluorescent antibody testing, reduced healthcare access, and incomplete surveillance may be contributing to these lower estimates.

Sebastien Kenmoe, B. Wahi-Singh, P. Wahi-Singh et al. · 0 citations
Open access Oct 2026

Effectiveness of RSV vaccine against cardio-respiratory hospitalizations in heart failure: a prespecified analysis of the DAN-RSV trial

Individuals living with heart failure (HF) are predisposed to severe cardio-respiratory disease (CRD) complications following respiratory syncytial virus (RSV) infection. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine reduced the risk of hospitalization for RSV-related respiratory tract disease (RTD),...

K. Skaarup, M. Lassen, M. Yafasov et al. · 0 citations
Open access Oct 2026

Effect of bivalent RSV prefusion F protein-based vaccine on myocarditis and pericarditis: a prespecified safety analysis of the DAN-RSV trial

Myocarditis and pericarditis are inflammatory cardiac syndromes that have been monitored as outcomes of special interest in adult vaccination programs. Previous randomized and observational studies of RSVpreF vaccination have not identified an association with these events; however, given their low incidence, pri...

M. Yafasov, M. Pareek, M. Lassen et al. · 0 citations
Open access Nov 2026

Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America.

INTRODUCTION Respiratory syncytial virus (RSV) and influenza cause substantial acute respiratory illness (ARI) and may be difficult to distinguish clinically. We compared characteristics of adults hospitalized with ARI, diagnosed with RSV versus influenza, using standardized systematic testing. METHODS The North Amer...

N. Aliabadi, Hammad Ali, Qing Liu et al. · 0 citations
Open access Oct 2026

Effectiveness of a bivalent RSV prefusion F protein-based vaccine in individuals with and without atherosclerotic cardiovascular disease: a prespecified analysis of the DAN-RSV trial

A prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD.

M. Pareek, M. Lassen, M. Yafasov et al. · 0 citations
Open access Sep 2026

Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons

Respiratory syncytial virus (RSV) protein subunit vaccines reduce the risk of severe outcomes such as hospitalization and emergency department (ED) visits for at least two RSV seasons following vaccination. No data have been published on real-world RSV vaccine effectiveness (VE) beyond the second season after vaccinati...

Sara Y. Tartof, E. Zasowski, N. Aliabadi et al. · 0 citations
Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · 1 citation
Open access Aug 2026

Seasonal dynamics and burden of respiratory syncytial virus, influenza, and COVID-19 in Brazil: a national surveillance study (2019–2023)

Background The burden and seasonal patterns of respiratory syncytial virus (RSV), influenza, and COVID-19 remain poorly characterised in Brazil and other Latin American countries. Understanding their epidemiological patterns is essential to inform public health interventions and preventive strategies. We aimed to asses...

G. S. Julian, J. Spinardi, Ana Paula Flora et al. · 0 citations
Open access Sep 2026

The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System

Precision of VE against RSV-related ARI ED/hospital admissions improved substantially with inclusion of salvage testing compared to SOC testing alone, suggesting that frequent standard-of-care RSV testing contributes to underestimated disease burden.

B. Ackerson, Brandon Chia, N. Aliabadi et al. · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations
Open access Sep 2026

Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial.

BACKGROUND Although evidence suggests some direct protection against Streptococcus pneumoniae serotype 3 (Spn3) from the 13-valent pneumococcal conjugate vaccine (PCV13), Spn3 remains a common cause of pneumococcal disease. We aimed to assess whether serotype-specific humoral immune responses to capsule polysaccharide...

P. Gonzalez-Dias, A. Gonçalves, J. Reiné et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.